The Third Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China.
School of Medicine & Holistic Integrative Medicine, Nanjing University of Chinese Medicine, Nanjing, China.
Signal Transduct Target Ther. 2021 Feb 24;6(1):78. doi: 10.1038/s41392-021-00486-7.
The abnormal regulation of alternative splicing is usually accompanied by the occurrence and development of tumors, which would produce multiple different isoforms and diversify protein expression. The aim of the present study was to conduct a systematic review in order to describe the regulatory mechanisms of alternative splicing, as well as its functions in tumor cells, from proliferation and apoptosis to invasion and metastasis, and from angiogenesis to metabolism. The abnormal splicing events contributed to tumor progression as oncogenic drivers and/or bystander factors. The alterations in splicing factors detected in tumors and other mis-splicing events (i.e., long non-coding and circular RNAs) in tumorigenesis were also included. The findings of recent therapeutic approaches targeting splicing catalysis and splicing regulatory proteins to modulate pathogenically spliced events (including tumor-specific neo-antigens for cancer immunotherapy) were introduced. The emerging RNA-based strategies for the treatment of cancer with abnormally alternative splicing isoforms were also discussed. However, further studies are still required to address the association between alternative splicing and cancer in more detail.
可变剪接的异常调控通常伴随着肿瘤的发生和发展,这会产生多种不同的异构体并使蛋白质表达多样化。本研究的目的是进行系统综述,以描述可变剪接的调控机制,以及其在肿瘤细胞中的功能,从增殖和凋亡到侵袭和转移,从血管生成到代谢。异常剪接事件作为致癌驱动因子和/或旁观者因子促进肿瘤进展。肿瘤中检测到的剪接因子改变以及肿瘤发生过程中的其他剪接错误(即长非编码 RNA 和环状 RNA)也包括在内。介绍了最近针对剪接催化和剪接调节蛋白的治疗方法,以调节病理性剪接事件(包括用于癌症免疫治疗的肿瘤特异性新抗原)。还讨论了基于 RNA 的新兴策略,用于治疗具有异常可变剪接异构体的癌症。然而,仍需要进一步的研究来更详细地阐明可变剪接与癌症之间的关系。